Cargando…
Effects of dalfampridine and its metabolites on cloned human potassium channels K(v) 1.1, K(v) 1.2, and K(v) 1.4 expressed in human embryonic kidney cells
BACKGROUND: Dalfampridine (4-aminopyridine; 4-AP) is a potassium channel blocker that has been available in the United States as a treatment to improve walking in patients with multiple sclerosis. 4-AP is well-characterized in vitro with regard to inhibition of neuronal potassium channels, but the p...
Autores principales: | Caggiano, Anthony, Blight, Andrew, Parry, Tom J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Maney Publishing
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4937658/ https://www.ncbi.nlm.nih.gov/pubmed/27536438 http://dx.doi.org/10.3109/21556660.2013.791623 |
Ejemplares similares
-
Identification of metabolites of dalfampridine (4-aminopyridine) in dog and rat
por: Caggiano, Anthony, et al.
Publicado: (2013) -
Identification of metabolites of dalfampridine (4-aminopyridine) in human subjects and reaction phenotyping of relevant cytochrome P450 pathways
por: Caggiano, Anthony, et al.
Publicado: (2013) -
Imiquimod enhances excitability of dorsal root ganglion neurons by inhibiting background (K(2P)) and voltage-gated (K(v)1.1 and K(v)1.2) potassium channels
por: Lee, Jaekwang, et al.
Publicado: (2012) -
An epilepsy-associated K(V)1.2 charge-transfer-center mutation impairs K(V)1.2 and K(V)1.4 trafficking
por: Nilsson, Michelle, et al.
Publicado: (2022) -
Tuning Scorpion Toxin Selectivity: Switching From K(V)1.1 to K(V)1.3
por: Gigolaev, Andrei M., et al.
Publicado: (2020)